Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): A multicentre, randomised open-label trial

The Lancet

Volumn 379, Issue 9833, 2012, Pages 2262-2269

  Aschner, Pablo ^a   Chan, Juliana ^b   Owens, David R ^c   Picard, Sylvie ^d   Wang, Edward ^e   Dain, Marie Paule ^e   Pilorget, Valérie ^e   Echtay, Akram ^f   Fonseca, Vivian ^g  

^a PONTIFICIA UNIVERSIDAD JAVERIANA   (Colombia)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c CARDIFF UNIVERSITY   (United Kingdom)

^d Point Medical Rond Point de la Nation   (France)

^e SANOFI   (France)

^f RAFIC HARIRI UNIVERSITY HOSPITAL   (Lebanon)

^g TULANE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN GLARGINE; METFORMIN; SITAGLIPTIN;

ACUTE HEART INFARCTION; ADULT; AGED; ANEMIA; ANGINA PECTORIS; ARTICLE; BODY MASS; CAROTID ARTERY OBSTRUCTION; CELLULITIS; CONSCIOUSNESS DISORDER; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPILEPSY; FALSE ANEURYSM; FEMALE; GLUCOSE BLOOD LEVEL; HEMORRHAGIC ANEMIA; HUMAN; HYPERTENSION; HYPOGLYCEMIA; INFLUENZA; INJECTION SITE INFLAMMATION; INTESTINE DIVERTICULOSIS; INTOXICATION; KAPOSI SARCOMA; KIDNEY COLIC; LEG PAIN; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; NAUSEA; NERVE COMPRESSION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONCARDIAC CHEST PAIN; ORTHOSTATIC HYPOTENSION; PERIANAL ABSCESS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; STOMACH EMPTYING; TREATMENT OUTCOME; UNCONSCIOUSNESS; UNSTABLE ANGINA PECTORIS; URETER STONE; VASCULAR PSEUDOANEURYSM;

EID: 84862271963     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)60439-5     Document Type: Article

References (25)

1. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-89.
2. Ray KK, Seshasai SRK, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009; 373: 1765-72.
3. Turnbull FM, Abraira C, Anderson RJ, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009; 52: 2288-98.
4. IDF Clinical Guidelines Task Force. Guideline for management of postmeal glucose. Brussels: International Diabetes Federation, 2007. http://www.idf.org/ webdata/docs/Guideline-PMG-final.pdf (accessed Jan 10, 2012).
5. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009; 52: 17-30.
6. Rodbard HW, Blonde L, Braithwaite SS, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007; 13 (suppl 1): 1-68.
7. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006; 29: 2638-43.
8. Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007; 9: 194-205.
9. Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 3080-86.
10. Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 2008; 51: 408-16.
11. Fonseca V, Gill J, Zhou R, Leahy J. An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia. Diabetes Obes Metab 2011; 13: 814-22.
12. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ 2011; 343: d4169.
13. Mannucci E, Monami M, Lamanna C, Gori F, Marchionni N. Prevention of cardiovascular disease through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 2009; 19: 604-12.
14. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.
15. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-65.
16. Hemmingsen B, Lund SS, Gluud C, et al. Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ 2011; 343: d6898.
17. Ahren B. Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin. Diabetes Metab Syndr Obes 2010; 3: 31-41.
18. Wainstein J, Katz L, Engel SS, et al. Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes. Diabetes Obes Metab 2011; 14: 409-18.
19. Triplitt C, Glass L, Miyazaki Y, et al. Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea. Diabetes Care 2006; 29: 2371-77.
20. Weng J, Li Y, Xu W, et al. Effect of intensive insulin therapy on β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 2008; 371: 1753-60.
21. Noh YH, Lee SM, Kim EJ, et al. Improvement of cardiovascular risk factors in patients with type 2 diabetes after long-term continuous subcutaneous insulin infusion. Diabetes Metab Res Rev 2008; 24: 384-91.
22. Chen HS, Wu TE, Jap TS, Hsiao LC, Lee SH, Lin HD. Beneficial effects of insulin on glycemic control and beta-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy. Diabetes Care 2008; 31: 1927-32.
23. Desouza CV, Bolli GB, Fonseca V. Hypoglycemia, diabetes, and cardiovascular events. Diabetes Care 2010; 33: 1389-94.
24. Pozzilli P, Leslie RD, Chan J, et al. The A1C and ABCD of glycaemia management in type 2 diabetes: a physician's personalized approach. Diabetes Metab Res Rev 2010; 26: 239-44.
25. Gerstein H, Yusuf S, Riddle MC, Ryden L, Bosch J. Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). Am Heart J 2008; 155: 26-32.